About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Logout
Obstetrics and Gynegology2019№12
Current trends in the management...

Current trends in the management of bacterial vaginosis

DOI
https://dx.doi.org/10.18565/aig.2019.12.193-196

Apolikhina I.A., Afendieva Z.N.

1) V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia
Despite the fact that ICD-10 does not encode bacterial vaginosis (BV) as a separate disease; today it is an unresolved reproductive health problem in women and along with other vulvovaginal infections remains one of the most common reasons for visiting a gynecologist. The paper reviews the data available in world and Russian literature on the efficacy and safety of dequalinium chloride used to treat BV. It discusses the mechanisms for the emergence of resistance of microorganisms to standard therapy regimens and the benefits of alternative treatments. The paper provides the 2018 clinical recommendations of the International Union Against Sexually Transmitted Infections (IUSTI)/World Health Organization (WHO) for the management of patients with pathological vaginal discharge. By taking into account a wide range of actions, evidence-based therapy effective against anaerobic and aerobic bacteria, fungi, and protozoa, the lack of resistance in microorganisms, and the possibility of use in all trimesters of pregnancy and during lactation, dequalinium chloride can be recommended as the drug of choice for the therapy of bacterial vaginosis caused by pathogens, including A. vaginae resistant to standard treatment regimens.

Keywords

bacterial vaginosis
vulvovaginal infections
antibiotic resistance
dequalinium chloride
Full text (in Russian)

References

  1. Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин /РОАГ/ под ред. В.Н. Прилепской, Е.Ф. Кира. 2019. 57 с. [Klinicheskie rekomendacii po diagnostike i lecheniju zabolevanij, soprovozhdajushhihsja patologicheskimi vydelenijami iz polovyh putej zhenshhin /ROAG/ pod red. V.N. Prilepskoj, E.F. Kira. 2019. 57 s. (in Russian)].
  2. Borgdorff H., Armstrong S.D., Tytgat H.L., Xia D., Ndayisaba G.F., Wastling J.M., van de Wijgert J.H. Unique insights in the cervicovaginal Lactobacillus iners and L. crispatus proteomes and their associations with microbiota dysbiosis. PLoS One. 2016; 11(3): e0150767. https://dx.doi.org/10.1371/journal.pone.0150767
  3. Nasioudis D., Linhares I.M., Ledger W.J., Witkin S.S. Bacterial vaginosis: a critical analysis of current knowledge. BJOG. 2017. 124: 61–9. doi: 10.1111/1471-0528
  4. Mehta S.D. Systemic review of randomized trials of treatment of male sexual partners for improved bacterial vaginosis outcomes in women. Sex Transm Dis. 2012; 39(10): 822–30. doi: 10.1097/OLQ.0b013e3182631d89
  5. Verstraelen H., Verhelst R., Vaneechoutte M., Temmerman M. The epidemiology of bacterial vaginosis in relation to sexual behaviour. BMC Infect Dis. 2010; 10: 81. doi: 10.1186/1471-2334-10-81.
  6. Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet.Gynecol.Surv. 2010; 65: 462–73. doi: 10.1097/OGX.0b013e3181e09621.
  7. Forsum U., Holst E., Larsson P.G., Vasquez A., Jakobsson T., Mattsby-Baltzer I. Bacterial vaginosis – a microbiological and immunological enigma. APMIS. 2005; 113: 81–90. doi: 10.1111/j.1365-2672.2011.04977.x
  8. Marrazzo J.M. A persistent(ly) enigmatic ecological mystery: bacterial vaginosis. J Infect Dis 2006; 193: 1475–7. doi: 10.1086/503783
  9. Donders G.G., Van C.C., Bellen G., et al. Association between abnormal vaginal flora and cervical length as risk factors for preterm birth. Ultrasound Obstet. Gynecol. 2010. doi: 10.1002/uog.7568
  10. Kenyon C., Colebunders R., Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013; 209(6): 505–23.doi: 10.1016/j.ajog.2013.05.006
  11. Bretelle F., Rozenberg P., Pascal A., Favre R., Bohec C., Loundou A., Senat M.V., Aissi G., Lesavre N., Brunet J., et al. High Atopobium vaginae and Gardnerella vaginalis vaginal loads are associated with preterm birth. Clin Infect Dis. 2015; 60: 860–7. doi: 10.1093/cid/ciu966
  12. Российское общество дерматовенерологов и косметологов, Российское общество акушеров-гинекологов. Федеральные клинические рекомендации по ведению больных бактериальным вагинозом. Акушерство и гинекология. 2016; Приложение № 4: 42–8. [Russian Society of Dermatovenerologists and Cosmetologists, Russian Society of Obstetricians and Gynecologists. Federal clinical guidelines for the management of patients with bacterial vaginosis. Obstetrics and gynecology. 2016; Appendix No. 4: 42–8. (in Russian)]
  13. Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis. 2009; 22(1): 82–6. doi: 10.1097/QCO.0b013e32832180c6
  14. Sherrard J., Wilson J., Donders G., Mendling W., Jensen J.S. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int. J. STD AIDS. 2018; 29(13): 1258–72. doi: 10.1177/0956462418785451
  15. Hugo W.B., Frier M. Mode of action of the antibacterial compound dequalinium acetate. Appl Microbiol. 1969; 17:118–27. PMCID: PMC377624
  16. Donders G.G., Zodzika J., Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother. 2014; 15: 645–57. doi: 10.1517/14656566.2014.881800
  17. Lopes dos Santos Santiago G., Grob P., Verstraelen H., Waser F., Vaneechoutte M. Susceptibility testing of Atopobium vaginae for dequalinium chloride. BMC Res Notes. 2012 ; 5: 151. doi: 10.1186/1756-0500-5-151
  18. Зильберберг Н.В., Грекова Ю.Н., Левчик Н.К., Евстигнеева Н.П., Воронова О.А., Герасимова Н.А. Принципы терапии бактериального вагиноза, ассоциированного с Gardnerella vaginalis и Atopobium vaginae, у женщин репродуктивного возраста. Вопросы гинекологии, акушерства и перинатологии. 2018; 17(6): 19–25. [Zilberberg N.V., Grekova Yu.N., Levchik N.K., Evstigneeva N.P., Voronova O.A., Gerasimova N.A. Principles for the treatment of bacterial vaginosis associated with Gardnerella vaginalis and Atopobium vaginae in women of reproductive age. Questions of gynecology, obstetrics and perinatology. 2018; 17 (6): 19–25. (in Russian)]. doi: 10.20953/1726-1678-2018-6-19-25
  19. Енькова Е.В., Хоперская О.В., Гайская О.В., Атякшин Д.А., Енькова В.В., Сенцова Е.Я. Влияние нарушений вагинального биоценоза на популяцию тучных клеток децидуальной ткани в I триместре беременности. Вопросы гинекологии, акушерства и перинатологии. 2019; 18(2): 76–82. [Enkova E.V., Khoperskaya O.V., Gayskaya O.V., Atyakshin D.A., Enkova V.V., Sentsova E.Ya. The effect of vaginal biocenosis disorders on the mast cell population of decidual tissue in the first trimester of pregnancy. Questions of gynecology, obstetrics and perinatology. 2019; 18 (2): 76–82. (in Russian)]. doi: 10.20953/1726-1678-2019-2-76-82
  20. Hijona J.J., Carballo A.L., Sánchez M.S., Dyachkova N., Expósito J.F.,Alcázar J.L. Vaginal antiseptics reduce the risk of perinatal infection with group B streptococci. The Journal of Maternal-Fetal & Neonatal Medicine. 2018; 32: 2741–45. doi: 10.1080/14767058.2018.1449196
  21. Радзинский В.Е., Ордиянц И.М., Четвертакова Э.С., Мисуно О.А. Двухэтапная терапия вагинальных инфекций. Акушерство и гинекология. 2011; 5: 90–3. [Radzinsky V.E., Ordiyants I.M., Chetvertakova E.S., Misuno O.A. Two-stage therapy for vaginal infections. Akusherstvo i Ginekologiya/ Obstetrics and gynecology. 2011; 5: 90–3. (In Russian)].

Received 11.11.2019

Accepted 29.11.2010

About the Authors

Inna A. Apolikhina, MD, Head of the Department of Aesthetic Gynecology and Rehabilitation of National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov. Professor of the Depertment of Obstetrics, Gynecology, Perinatology and Reproductology, Institute of Professional Education of the I.M. Sechenov First MSMU of Ministry of Health of Russia (Sechenov University). E-mail: i_apolikhina@oparina4.ru
117997, Russia, Moscow, Ac. Oparina str. 4.
Zulphiya N. Efendieva, postgraduate student at the Depertment of Obstetrics, Gynecology, Perinatology and Reproductology, Institute of Professional Education
of the I.M. Sechenov First MSMU of Ministry of Health of Russia (Sechenov University). E-mail: efendievaz@yandex.ru.
Address: 119991, Russia, Moscow, ul. Bolshaya Pirogovskaya, 2/ 4.

For citation: Apolikhina I.A., Efendieva Z.N. Current trends in the management of bacterial vaginosis.
Akusherstvo i Ginekologiya / Obstetrics and gynecology. 2019; 12: 193-6.(In Russian).
https://dx.doi.org/10.18565/aig.2019.12.193-196

Similar Articles

№11 / 2021
Uruimagova A.T., Prilepskaya V.N., Mezhevitinova E.A., Donnikov A.E., Abakarova P.R., Dovletkhanova E.R., Gusakov K.I., Odyvanova A.A.
Efficiency and acceptability of two-stage therapy for recurrent bacterial vaginosis
№11 / 2023
Apolikhina I.A., Rakhmatulina М.R., Priputnevich Т.V., Gorbunova Е.А., Guschin А.Е., Potekaev N.N., Baranov I.I.
Systematic review of the efficacy and safety of nifuratel for women with diseases accompanied by pathological discharge from the genital tract
№1 / 2022
Lebedenko E.Yu., Gaida O.V., Mikhailenko Ya.V., Anufrieva V.G., Rymashevsky M.A., Sablina N. V., Bespalaya A. V.
Possibilities of alternative pharmacological approaches to monotherapy for bacterial vaginosis in reproductive-aged patients
№8 / 2023
Artymuk N.V., Marochko K.V., Parfenova Ya.A.
The effect of vaginal progesterone on the vaginal biocenosis in pregnant women with a high risk of preterm birth
№11 / 2023
Belyakina I.V., Galkina I.S., Shobolov D.L., Shtykunova E.V., Arantseva D.A.
Experience of clinical application of the Vapigel prebiotic in combined two-stage therapy of bacterial vaginosis in reproductive-aged women
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.